In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...

Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...

Dr. Nathan answers the question: 'What Are DPP-IV Inhibitors?' — -- Question: What are DPP-IV inhibitors and when are they used? Answer:The DPP-IV inhibitors are a very new class of drugs, and ...

Association driven by fewer major amputations ...

Please provide your email address to receive an email when new articles are posted on . “DPP-IV inhibitors and SGLT2 inhibitors are commonly used second-line antidiabetic medications,” Ching-Lung ...

Study results have validated that five routinely measured clinical values reliably identified patients with type 2 diabetes who had significantly different A1c responses to two important classes of ...

Please provide your email address to receive an email when new articles are posted on . Of 145,410 adults who began a GLP-1 drug, 76 developed thyroid cancer over a mean 3.9 years of follow-up. Risk ...

The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...